Leonteq Securities AG Takes $735,000 Position in Humana Inc. $HUM

Leonteq Securities AG bought a new stake in shares of Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,868 shares of the insurance provider’s stock, valued at approximately $735,000.

A number of other hedge funds have also recently modified their holdings of HUM. Revolve Wealth Partners LLC bought a new stake in shares of Humana during the 4th quarter valued at $202,000. Woodline Partners LP boosted its holdings in shares of Humana by 460.0% during the 1st quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after buying an additional 8,372 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Humana by 53.7% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock valued at $316,000 after buying an additional 452 shares in the last quarter. Cresset Asset Management LLC boosted its holdings in shares of Humana by 10.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock valued at $581,000 after buying an additional 222 shares in the last quarter. Finally, WINTON GROUP Ltd boosted its holdings in shares of Humana by 58.5% during the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock valued at $582,000 after buying an additional 879 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Insiders Place Their Bets

In other Humana news, insider Sanjay K. Shetty bought 810 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, with a total value of $150,020.10. Following the transaction, the insider owned 11,657 shares in the company, valued at $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.20% of the company’s stock.

Humana Price Performance

HUM opened at $307.79 on Friday. The stock has a 50-day moving average price of $218.13 and a 200-day moving average price of $227.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. The firm has a market cap of $36.95 billion, a PE ratio of 32.92, a P/E/G ratio of 2.82 and a beta of 0.68. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $315.66.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The business had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. During the same quarter in the previous year, the firm earned $11.58 EPS. Humana’s revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. Sell-side analysts predict that Humana Inc. will post 9.01 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.2%. Humana’s payout ratio is 37.86%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on HUM shares. Truist Financial boosted their target price on shares of Humana from $220.00 to $270.00 and gave the company a “hold” rating in a report on Thursday, April 30th. UBS Group lifted their price target on Humana from $262.00 to $320.00 and gave the stock a “neutral” rating in a research report on Friday. Evercore lifted their price target on Humana from $195.00 to $250.00 in a research report on Thursday, April 30th. Wells Fargo & Company lowered Humana from a “cautious” rating to a “reduce” rating in a research report on Wednesday. Finally, William Blair initiated coverage on Humana in a research report on Wednesday. They issued an “outperform” rating for the company. Nine analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $263.35.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.